Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Gold ETF median (25 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 21 Feb 2023 – 20 Aug 2026, limited by Mirae Asset Gold ETF. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Mirae Asset Gold ETF | Gold |
|---|---|---|
| 21 Feb 2023 | ₹100.00 | ₹100.00 |
| 07 Jun 2023 | ₹106.15 | ₹105.66 |
| 22 Sep 2023 | ₹104.50 | ₹104.06 |
| 06 Jan 2024 | ₹110.41 | ₹110.11 |
| 21 Apr 2024 | ₹129.14 | ₹128.97 |
| 06 Aug 2024 | ₹121.70 | ₹121.47 |
| 20 Nov 2024 | ₹132.84 | ₹132.03 |
| 06 Mar 2025 | ₹149.63 | ₹148.96 |
| 21 Jun 2025 | ₹171.38 | ₹170.39 |
| 05 Oct 2025 | ₹202.07 | ₹201.14 |
| 19 Jan 2026 | ₹247.96 | ₹250.93 |
| 06 May 2026 | ₹259.02 | ₹256.98 |
| 20 Aug 2026 | ₹269.20 | ₹267.05 |
| Metric | Mirae Asset NAV ₹151.39 Moderately High risk ★★★★★ | Category median Gold ETF · 25 funds |
|---|---|---|
| +57.07% | +57.05% | |
| +37.47% | +37.58% | |
| — | +25.96% | |
| — | +16.02% | |
| +32.77% | +29.06% | |
| +39.20% | — | |
| +34.66% | +12.13% | |
| — | +9.42% | |
| — | +8.74% | |
| Risk | ||
| 18.79% | 19.64% | |
| 1.65 | 1.65 | |
| 2.37 | 2.37 | |
| -22.10% | -22.15% | |
| Gold | — | |
| -1.27% | -1.56% | |
| 1.05 | 1.07 | |
| 99.4% | 99.8% | |
| 97.6% | 98.9% | |
| 0.35% | 0.50% | |
| ₹3,251Cr | ₹1,628Cr | |
| 0.05% | — | |
| None | — | |
| ₹99 | — | |
| ₹5.00K | — | |
| — | — | |
| Ritesh Patel · 1.8y | — | |
| 21 Feb 2023 | — | |
| — | — | |
| — | — | |
| -0.1% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.